SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw unusually large options trading on Friday. Investors acquired 79,890 call options on the stock. This is an increase of approximately 103% compared to the average volume of 39,383 call options.

SELLAS Life Sciences Group Price Performance

Shares of SELLAS Life Sciences Group stock traded up $2.04 during midday trading on Friday, reaching $15.44. The company had a trading volume of 12,469,392 shares, compared to its average volume of 8,233,277. SELLAS Life Sciences Group has a fifty-two week low of $1.39 and a fifty-two week high of $15.88. The stock has a fifty day moving average price of $11.69 and a 200 day moving average price of $7.67. The firm has a market cap of $3.12 billion, a PE ratio of -73.52 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its stake in shares of SELLAS Life Sciences Group by 86.6% in the 1st quarter. Bank of New York Mellon Corp now owns 478,366 shares of the company’s stock worth $2,023,000 after buying an additional 221,957 shares during the last quarter. Dagco Inc. lifted its holdings in shares of SELLAS Life Sciences Group by 19.8% in the 2nd quarter. Dagco Inc. now owns 1,232,433 shares of the company’s stock valued at $18,191,000 after acquiring an additional 203,653 shares during the last quarter. Fifth Third Bancorp bought a new stake in SELLAS Life Sciences Group in the first quarter worth $253,000. World Investment Advisors purchased a new stake in shares of SELLAS Life Sciences Group in the fourth quarter worth approximately $166,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in SELLAS Life Sciences Group by 408.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 55,129 shares of the company’s stock worth $208,000 after acquiring an additional 44,296 shares in the last quarter. Institutional investors own 17.38% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.